Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Osiris Therapeutics Tanked Today

By George Budwell - Feb 4, 2016 at 11:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A shake-up in leadership sent the stock reeling.

What: Shares of the regenerative-medicine company Osiris Therapeutics (NASDAQ: OSIR) fell by as much as 16% in early trading Thursday on modest volume after the company announced a major shake-up in its leadership team. Specifically, Dwayne Montgomery is taking over as interim CEO and Frank Czworka will become the company's new chief operating officer. This change in leadership was triggered by the resignation of the company's CEO Lode Debrabandere for "personal reasons."

So what: This change in leadership comes at an unfortunate time for the company. After all, Osiris is facing a class action lawsuit for allegedly overstating revenue and failing to follow GAAP standards in its quarterly financial reports. So, Debrabandere's sudden departure doesn't exactly inspire confidence in the company's ability to come out of this accounting mess unscathed. 

Now what: Osiris has struggled to shake off these allegations of accounting irregularities after its auditor BDO USA resigned last December. In fact, the company's shares are now down by over 40% in 2016, according to data compiled from S&P Capital IQ:

OSIR Chart

OSIR data by YCharts.

So, despite having a distribution agreement in place with the reputable Stryker Corporation for its bone allograft product Bio4, Osiris may still have further to fall because the sentiment surrounding this stock is simply so toxic right now. That's why I won't be picking up any shares in this struggling biotech -- even after this steep decline in share price. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.